Pricing Log in Create free account

Enanta Pharmaceuticals, Inc. (ENTA) vs Fulcrum Therapeutics, Inc. (FULC)

Enanta Pharmaceuticals, Inc. and Fulcrum Therapeutics, Inc. are both Biotechnology companies. Enanta Pharmaceuticals, Inc. and Fulcrum Therapeutics, Inc. are of similar size ($293.6M and $280.8M). Fulcrum Therapeutics, Inc. grew revenue faster over the last twelve months: 1,939.8% against 0.70%. Fulcrum Therapeutics, Inc. has the higher net margin (0.00% vs −96.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, Fulcrum Therapeutics, Inc. leads on 9 and Enanta Pharmaceuticals, Inc. on 5.

Valuation

Metric ENTA FULC Biotechnology median
P/E n/m n/m 10.60
P/S 4.90 3.43 9.40
P/B 3.17 0.91 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 0.38 0.66
EV/Sales 2.00 (0.44) 9.02
Earnings yield (21.91%) (32.61%) (32.88%)
Free cash flow yield (11.54%) (23.22%) (23.13%)

Profitability

Metric ENTA FULC Biotechnology median
Gross margin 100.00% 100.00% 68.51%
Operating margin (89.99%) 0.00% 0.00%
Net margin (96.89%) 0.00% 0.00%
Free cash flow margin (56.60%) 0.00% 0.00%
Return on equity (70.12%) (32.38%) (51.96%)
Return on assets (21.15%) (30.75%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ENTA FULC Biotechnology median
Revenue growth (TTM) 0.70% 1,939.80% 6.76%
EPS growth (last fiscal year) 29.93% (637.50%) 29.88%
Revenue growth, 5-year CAGR (11.81%) — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ENTA FULC Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.76 31.35 4.97
Net debt to EBITDA 2.35 4.23 1.01

Dividend

Metric ENTA FULC Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ENTA FULC Biotechnology median
Market cap 293.59m 280.77m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack